Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Hematologic Malignancy Reports|October 14, 2021
Future Directions in Chronic Phase CML TreatmentNathalie Javidi-Sharifi, Gabriela Hobbs
Hematological Oncology|June 15, 2025
Advances in the Management of Relapsed/Refractory CLL and Richter TransformationNathalie Javidi-Sharifi, Matthew S Davids
Expert Review of Hematology|May 24, 2024
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphomaNathalie Javidi-Sharifi, Jennifer R Brown
Seminars in Hematology|April 21, 2026
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigmsNathalie Javidi-Sharifi, Jennifer R Brown
Blood|January 11, 2014
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutationsElie Traer, Nathalie Javidi-Sharifi, Anupriya Agarwal, et al.
Cancer Research|September 28, 2016
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaElie Traer, Jacqueline Martinez, Nathalie Javidi-Sharifi, et al.
Cancer Research|November 30, 2014
Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug ResistanceNathalie Javidi-Sharifi, Elie Traer, Jacqueline Martinez, et al.
Oncogene|September 23, 2018
LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanomaLillian R Klug, Amber E Bannon, Nathalie Javidi-Sharifi, et al.
Elife|February 6, 2019
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cellsNathalie Javidi-Sharifi, Jacqueline Martinez, Isabel English, et al.
Blood Neoplasia|August 14, 2025
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemiaYesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, et al.
Pageof 2